14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Thu, 25 Apr 2024

Trading levels for BCRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.51 7.13 %
R2 4.42 4.95 %
R1 4.36 3.60 %
Current price: 4.21
Support S1 4.18 -0.752 %
S2 4.12 -2.10 %
S3 4.03 -4.28 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.14 22.09 %
R2 5.08 20.67 %
R1 5.00 18.76 %
Current price 4.21
Support S1 0 .
S2 0 .
S3 0 .

BCRX Predictions History

2 years ago
JS predicted that BCRX for 2022-03-29 is going $16.32 (-4.62%)

2 years ago
kevrafel8.312287 predicted that BCRX for 2022-03-29 is going

Rank:

2 years ago
Banti Gullapalli predicted that BCRX for 2021-07-13 is going

Rank:

3 years ago
JS predicted that BCRX for 2021-02-03 is going $10.06 (-2.33%)

3 years ago
Eli Galka predicted that BCRX for 2021-02-03 is going $10.53 (2.23%)

Rank:

3 years ago
JS predicted that BCRX for 2021-01-25 is going $9.30 (1.53%)

3 years ago
Murali Prabhu predicted that BCRX for 2021-01-25 is going $6.00 (-34.85%)

Rank:

3 years ago
JS predicted that BCRX for 2020-12-21 is going $8.78 (5.78%)

3 years ago
Alan predicted that BCRX for 2020-12-21 is going $8.80 (2.21%)

3 years ago
JS predicted that BCRX for 2020-11-30 is going $4.94 (-3.33%)

Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT